Eikon Therapeutics · 20 hours ago
Principal Scientist, Computational Chemistry
Millbrae, CA
Full-time
Onsite
Lead/Staff
$204K/yr - $223K/yr
10+ years expEikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the intersection of chemistry, engineering, computation, and biology to discover novel treatments for life-threatening diseases. The Principal Scientist in Computational Chemistry will apply in silico technologies and AI/ML to drive the discovery of lead-like molecules and collaborate with various teams to accelerate the drug discovery process.
BiotechnologyHealth CareLife ScienceMedical
Responsibilities
Deliver virtual screening workflows that leverage physics- and AI-based modeling methods involving ligand- and structure-based methods, ensemble docking, molecular dynamics, and free energy calculations
Provide computational chemistry program support across our drug discovery pipeline spanning target selection, HTS, hit identification/calling, hit to lead, and lead optimization
Provide guidance on the application of modern cheminformatics, ML/AI methods for library design (e.g. diversity, focused, fragment, DEL) and analyzing large datasets from HTS campaigns to building predictive models from them
Routinely employ expert knowledge and analysis of SAR, physiochemical and ADMET properties
Work alongside medicinal chemists to further triage emerging hits for synthesis/purchase
Collaborate closely with our data science team to integrate cutting edge AI/ML tools into our chemistry and drug discovery processes
Qualification
Required
PhD in Computational Chemistry or related discipline with +10 years of relevant experience; or Master's plus 18 years of relevant experience; or Bachelor's plus 20 years of relevant experience
Expertise in virtual screening, HTS triaging, hit calling, and diversity analysis
Expertise in computational chemistry software, such as Schrödinger Suite, Rosetta, AlphaFold, Gromacs, or similar tools
Expertise with physics-based methods, molecular dynamics, conformational analysis, free energy perturbation, and quantum mechanics
Expertise in cheminformatics data analysis, data mining and machine learning models to solve drug discovery problems
Experience with ligand-based design approaches, QSAR, QSPR, multiparameter optimization to rationalize SAR and design novel molecules
A track record of publications, patents and/or conference presentations in computational chemistry and/or drug discovery
Proficient in scientific programming (e.g. python, KNIME) and data analytics (Spotfire, DataWarrior, Pandas)
Excellent problem-solving abilities and the ability to work in a fast-paced, dynamic research environment
Strong communication skills with the ability to convey complex scientific concepts to both technical and non-technical stakeholders
Benefits
401k plan with company matching
Medical (premiums covered by Eikon at 95%), dental and vision insurance (premiums covered by Eikon at 100%)
Mental health and wellness benefits
Weeklong summer and winter holiday shutdowns
Generous paid time off and holiday policies
Life/AD&D Insurance (premiums covered by Eikon at 100%) and optional supplemental employee-paid life/AD&D policies
Enhanced parental leave benefit
Daily subsidized lunch program when on-site
Company
Eikon Therapeutics
Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.
201-500 employees
H1B Sponsorship
Eikon Therapeutics has a track record of offering H1B sponsorships. Please note that this does not
guarantee sponsorship for this specific role. Below presents additional info for your
reference. (Data Powered by US Department of Labor)
Distribution of Different Job Fields Receiving Sponsorship
Represents job field similar to this job
Trends of Total Sponsorships
2025 (12)
2024 (17)
2023 (7)
2022 (3)
2021 (1)
Funding
Current Stage
Late StageTotal Funding
$1.12BKey Investors
The Column Group
2025-02-26Series D· $350.7M
2023-06-01Series C· $106M
2022-01-06Series B· $518M
Leadership Team
Roger Perlmutter
Chairman, President, and CEO
Michael Klobuchar
Chief Operating Officer
Recent News
2026-01-19
pharmaphorum
2026-01-14
Company data provided by crunchbase